Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Completed Not applicable Interventional Results available

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

NCT02734667
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM at diagnosis of T1D
Device
Lead sponsor
Korey Hood
Other
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Standard of Care
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

NCT00211536
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
Drug · Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
5
States / cities
Santa Barbara, California • Aurora, Colorado • North Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
View directory record Official record
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

Effect of Gain on Closed-Loop Insulin

NCT02065895
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIGH error, NO error, LOW error
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 13, 2026, 9:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References

NCT01415544
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
Interventions
Not listed
Lead sponsor
InLight Solutions
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of C-peptide on Hypoglycemic Counterregulation

NCT06470295
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Saline, C-peptide
Other · Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes

NCT00896077
View directory record Official record
Conditions
Healthy, Type 1 Diabetes
Interventions
Lisofylline
Drug
Lead sponsor
DiaKine Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional

B-Lymphocyte Immunotherapy in Islet Transplantation

NCT00468442
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab, Rituximab, Sirolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Pilot Study of Remote Glucose Monitoring Among Pediatric Patients With Type 1 Diabetes

NCT04696640
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Remote Patient Monitoring
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 20 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Imaging of Type 1 Diabetes Progression

NCT01521520
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ferumoxytol
Drug
Lead sponsor
Jason Gaglia
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Early Phase 1 Interventional

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

NCT01954459
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insupatch, Continuous glucose sensor
Device
Lead sponsor
Yale University
Other
Eligibility
8 Years to 44 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional

MyT1DHero: an mHealth Intervention for Type 1 Diabetes

NCT03521362
View directory record Official record
Conditions
Type1diabetes
Interventions
MyT1DHero, Other T1D Mobile App
Device
Lead sponsor
Michigan State University
Other
Eligibility
10 Years to 15 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

NCT02236754
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
18 F-FP-DTBZ, PET Scanning
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

NCT01194245
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

NCT07579702
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Omnipod 5 System, Omnipod 6 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
14 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Laser and Antioxidant Treatment of Diabetic Macular Edema

NCT00055042
View directory record Official record
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

Lactobacillus Johnsonii in Children and Adolescents With T1D

NCT03961854
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
L. johnsonii Probiotic, Placebo Capsule
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

NCT00751842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
rhGAD65, Placebo
Drug
Lead sponsor
Diamyd Therapeutics AB
Industry
Eligibility
10 Years to 20 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational

Gene Expression Profiling in Type 1 Diabetes

NCT00330954
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 14 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

NCT00315627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes

NCT04190368
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Team Clinic Care, Standard Care
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 13, 2026, 9:22 PM EDT